In a first-in-human Phase 1 study in healthy volunteers (n=59), Spyre Therapeutics’ extended half-life anti-IL-23 antibody SPY003 was well...

Preclinical data presented at the World ADC San Diego meeting show that incorporating Lisata’s iRGD cyclic peptide, certepetide, as...

Hengrui’s once-weekly dual GLP-1/GIP agonist HRS9531 delivered 48-week mean weight loss of 11.2%, 17.4%, and 19.2% at 2 mg,...

In preclinical diet-induced obesity models, Aardvark’s fixed-dose candidate ARD-201 reduced body weight by roughly 19% over 30 days, comparable...

Reviva will present new analyses on negative symptoms with brilaroxazine from its Phase 3 RECOVER double‑blind trial in acutely...

In a registrational Phase II study of 72 evaluable patients with relapsed/refractory CLL/SLL after BTK inhibitor exposure, lisaftoclax monotherapy...

At the SCOPE 2025 Europe conference, during a panel titled, “Trials Are Leaving Europe — Can We Bring Them...

Early Phase 1b signals from Fulcrum’s PIONEER study suggest pociredir, an oral EED inhibitor, increases fetal hemoglobin to levels...

In pooled 8‑week induction data from the Phase 3 ABTECT‑1 and ABTECT‑2 trials in moderate‑to‑severe ulcerative colitis, 37% of...

Three-year follow-up from Ascendis Pharma’s PaTH Forward (Phase 2) and PaTHway (Phase 3) trials in adults with chronic hypoparathyroidism...